Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases.
Publication/Presentation Date
3-1-2013
Abstract
Peritoneal metastasis is a significant clinical challenge; life expectancy following diagnosis is usually very short. Surgical cytoreduction with HIPEC is being used with increasing frequency in selected patients; most outcome data have shown that prolonged median survivals can be observed in selected patients. This review summarizes the published data related to outcome and quality of life after cytoreduction and HIPEC to provide insights into its use in patients with peritoneal carcinomatosis.
Volume
4
Issue
1
First Page
62
Last Page
71
ISSN
2078-6891
Published In/Presented At
Zhu, Y., Hanna, N., Boutros, C., & Alexander, H. R., Jr (2013). Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases. Journal of gastrointestinal oncology, 4(1), 62–71. https://doi.org/10.3978/j.issn.2078-6891.2012.053
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
23450068
Department(s)
Administration and Leadership
Document Type
Article